Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose is to study the safety of AZD1305, how AZD1305 is tolerated and how the medication is metabolised by the body (how it is taken up into the body, distributed around the body and disappears from the body
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A | Experimental | AZD1305 solution for iv infusion |
|
| B | Placebo Comparator | NaCl solution for iv infusion |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AZD1305 | Drug | Solution for iv infusion , single dose |
| |
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse events, ECG variables, vital signs, physical examination, laboratory variables, body temperature and weight | During the study |
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetic variables | During all dosing visits |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Helen Lunde, MD | AstraZeneca R&D, Mölndal, Sweden | Study Director |
| Marianne Hartford, MD, PhD | AstraZeneca, Clinical Pharmacology Unit, Sahlgrenska University Hospital, Göeborg, Sweden | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Uppsala | Sweden |
Not provided
| ID | Term |
|---|---|
| C550721 | tert-butyl (2-(7-(2-(4-cyano-2-fluorophenoxy)ethyl)-9-oxa-3,7-diazabicyclo(3.3.1)non3-yl)ethyl)carbamate |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
NaCl solution for iv infusion, single dose |
|